|Bid||8.06 x 1400|
|Ask||8.08 x 800|
|Day's Range||8.03 - 8.57|
|52 Week Range||7.74 - 36.14|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2023 - Aug 04, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.75|
Subscribe to Yahoo Finance Plus to view Fair Value for EBSLearn more
BIDU, EBS and FRO have been added to the Zacks Rank #5 (Strong Sell) List on May 17, 2023.
Emergent BioSolutions (NYSE: EBS) has been quite the up-and-down stock of late. On Monday, it had an up session on the market, creeping northward by 1.2% and exceeding the S&P 500's gain of 0.3%. The buyer is Denmark-headquartered peer Bavarian Nordic, which has handed over $270 million for the set of assets.
GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it has completed the sale of its travel health business to Bavarian Nordic (OMX: BAVA). At closing Emergent received $270 million, subject to customary closing adjustments, and may receive up to an additional $110 million in potential future milestone payments. With the transaction closed, Bavarian Nordic has acquired the rights to Vivotif®, the licensed typhoid vaccine, and Vaxchora®, the licen
GAITHERSBURG, Md., May 11, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2023 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 25, 2023 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETINGAs described in the proxy materials, stockholders of record are eligible to participate in and ask questions during the Virtual Annual Meeting by visiting www.virtualshareholdermeeting.com/EBS2023
Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.
Q1 2023 Emergent BioSolutions Inc Earnings Call
The company is prepping over-the-counter sales of the opioid overdose drug — and recently named its price.
My name is Bob Burrows. Thank you for joining us today as we discuss the operational and financial results for the first quarter of 2023. As is customary, today's call is open to all participants in the call is being recorded and is copyrighted by Emergent BioSolutions.
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -89.82% and 15.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101MUpdates FY 2023 guidance and provides initial Q2 2023 guidance GAITHERSBURG, Md., May 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2023. Among the highlights, Emergent has received from the U.S. government Notices of Intent to Purchase medical countermeasures to combat smallpox
Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.
Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
By Vlad Schepkov
Contract drugmaker Emergent BioSolutions Inc said on Thursday it is aiming to price the over-the-counter (OTC) version of its opioid overdose reversal drug Narcan at around $50 per carton. The OTC version will become available at U.S. stores and online retailers later this summer, while the currently available prescription nasal spray carries a wholesale price tag of $125 per carton. Emergent's statement comes nearly a month after the U.S. Food and Drug Administration allowed Narcan to be sold over-the-counter, allowing for easier availability of the life-saving medication.
GAITHERSBURG, Md., April 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the second quarter of 2023, and financial outlook for full year 2023. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent’s website. To partici
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
The biotech plans to launch the over-the-counter product this summer, beating competitors to the punch.
Shares of Emergent BioSolutions (NYSE: EBS) were soaring 11% higher as of 11:13 a.m. ET on Thursday. The big gain came after the Food and Drug Administration (FDA) approved the company's Narcan on Wednesday as an over-the-counter (OTC) treatment for opioid overdoses. Emergent's Narcan has been available since 2016 as a prescription drug for opioid overdose.
Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Narcan, a standard treatment for opioid overdoses, will become available in U.S. retail stores later this year, as part of health officials’ efforts to reduce the number of fatal overdoses. The move should also pave the way for growing sales for Emergent Biosolutions which produces Narcan. On Wednesday, the Food and Drug Administration approved Narcan, a naloxone hydrochloride nasal spray, for over-the-counter use.
The FDA has approved Emergent BioSolutions Inc's (NYSE: EBS) Narcan, 4 milligrams (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription use – the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose. The move paves the way for the medication to reverse an opioid overdose to be sold directly to consumers in drug stores, convenienc
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
For the first time since the opioid crisis began, people will be able to buy medication on retail shelves to reverse an overdose.
NARCAN® Naloxone HCl Nasal Spray 4 mg is currently the first and only prescription strength naloxone nasal spray to receive over-the-counter status in the U.S., which is a critical step toward broadening accessExpected over-the-counter availability is anticipated by late summer of this year GAITHERSBURG, Md., March 29, 2023 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved NARCAN® Naloxone HCl Nasal Spray 4 m